Меню
Идёт набор NCT07520045

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

Без фазы С лечением Diabetic Retinopathy (DR) Diabetic Macular Edema (DME)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Faricimab, Biosimilar ranibizumab.
Кому может быть актуально
Состояния в реестре: Diabetic Retinopathy (DR), Diabetic Macular Edema (DME). Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Хорватия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Comparative Analysis of OCT and OCT Angiography Biomarkers and Systemic Laboratory Parameters in Patients With Diabetic Retinopathy Undergoing Treatment With Faricimab or Biosimilar Ranibizumab Following Three Loading Doses

Обзор

The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomarkers predict early treatment response? How do imaging biomarkers change after three loading doses of treatment? Are imaging biomarkers associated with systemic laboratory parameters? Researchers will compare faricimab to biosimilar ranibizumab to see if there are differences in imaging biomarkers and early treatment response. Participants will: * be randomized in a 1:1 ratio using a computer-generated randomization sequence * undergo comprehensive ophthalmic examinations, including visual acuity and intraocular pressure measurement * undergo OCT and OCT angiography imaging at each visit * receive three intravitreal injections during the loading phase * attend follow-up visits from baseline to 4-5 weeks after the third injection * provide blood samples for systemic laboratory analysis

Вмешательства

  • Препарат Faricimab
    Faricimab will be administered via intravitreal injection.
  • Препарат Biosimilar ranibizumab
    Biosimilar ranibizumab will be administered via intravitreal injection.

Первичные конечные точки

  • Comparison of OCT and OCTA biomarkers associated with early anatomical treatment response to faricimab and biosimilar ranibizumab [Срок оценки: From enrollment to 4-5 weeks after the third intravitreal injection]
Вторичные конечные точки (1)
  • Association between blood-derived laboratory parameters and imaging-based treatment response [Срок оценки: From enrollment to 4-5 weeks after the third intravitreal injection]

Критерии участия

Критерии включения

  • Adults aged ≥18 years
  • Diabetic retinopathy with or without central macular edema
  • Indication for intravitreal anti-VEGF therapy according to current clinical guidelines
  • Ability to provide written informed consent

Критерии исключения

  • Intravitreal anti-VEGF or corticosteroid treatment in the study eye within 5 months prior to enrollment
  • Any intraocular surgery (including cataract surgery) 3 months prior intraocular surgery to enrollment
  • Retinal laser photocoagulation in the study eye within 3 months prior to enrollment
  • Presence of other ocular, retinal or macular diseases that may affect OCT/OCTA findings or visual acuity (e.g., age-related macular degeneration, retinal vascular occlusions)
  • Retinal detachment, preretinal fibrosis, vitreomacular traction
  • Significant media opacities (e.g., dense cataract, vitreous hemorrhage) precluding reliable OCT/OCTA imaging
  • Uncontrolled glaucoma (intraocular pressure > 30 mmHg in study eye)
  • Active ocular inflammation
  • Suspected active ocular infection in either eye
  • Any febrile illness within 1 week prior to first injection
  • History or presence of any clinically significant disease, non-diabetic metabolic disorder, abnormal physical examination finding, or laboratory abnormality that, in the opinion of the investigator, may contraindicate treatment with faricimab or biosimilar ranibizumab, interfere with the interpretation of study results, or place the participant at increased risk of treatment-related complications.
  • Women who are pregnant, breastfeeding, or planning pregnancy within the next 100 weeks
  • Known hypersensitivity to faricimab or biosimilar ranibizumab or any of its excipients
  • Participation in another clinical trial that may affect study outcomes
  • Inability to comply with study procedures or follow-up

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Лечение

Центры проведения

Хорватия · 1 центр
  • University Hospital Osijek — Osijek

Идентификаторы

NCT: NCT07520045 · R1-2689/2026.

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗